Its moneylife article behind the paywall. But the gist of the article is as below
- Mainly focusses on valuation of Piramal Pharma, which is 60% CDMO business, 30% Complex Hospital Generics and 10% India Consumer products business.
- Compared with Divis, Syngene, Suven Pharma and PI Industries mainly as they are comparable CDMO players
- Price to sales ratio of Divis is 19, Suven -15, PI and Syngene at 12
- Applying median P/S ratio of 14, valuation of Piramal Pharma comes to 76,000Cr
- Combined entity PEL valuation/market cap is around 38,000 Cr which means market is giving negative (-)38,000 cr valuation to financial business.
- Book value of fin business is 20,000. using ratio of P/b of 2, valuation of fin business should be around 40,000 Cr
- So fair value of total business comes to 116,000 Cr , 3 times current level
- Maybe there is conglomerate discount which will go away as soon market gets whiff of spinoff , which can happen sooner rather than later.